Business Development Market

Dalia S. Gilgoff

Doylestown, PA 215-***-**** *****.*******@*****.*** linkedin.com/in/dalia-gilgoff BIOPHARMA COMMERCIAL STRATEGY LEADER

Market Development Product Launch Brand Strategy Clinical Development Strategy Results-driven Senior Marketing professional with demonstrated expertise in marketing strategy, implementation, product launch and commercial leadership. Drive innovative, differentiated asset and portfolio level commercialization strategy. Proven expertise in launching successful promotional campaigns, driving product awareness, and shaping commercially attractive programs. Demonstrated executive presence with a track record of influencing without authority and driving cross- functional alignment. Deep therapeutic expertise in Hematology / Oncology, Inflammation and Immunology, and Vaccines AREAS OF EXPERTISE

New Product Development Business Analytics/Insights Project Management Marketing Campaigns Cross-Functional Leadership New Business Development Lifecycle/Business Development Assessments Go-To-Market Strategy KOL & PAG collaborations Competitive Intelligence Product Launch Strategy Budgeting & Forecasting Industry Partnerships PROFESSIONAL EXPERIENCE

Pfizer, Inc Collegeville, PA

Hematologic Malignancies Market Development Lead, 2022 - 2024 Lead global launch preparation (L-3) of maplirpacept, a novel and best-in-class CD47, in five hematologic indications, including AML, Multiple Myeloma, and Lymphoma. Develop and implement short and long-term brand strategy to drive awareness and education of maplirpacept’s differentiated MoA and clinical development program. Developed a leadership-endorsed holistic lifecycle plan to maximize value of asset within 3 months of being in role.

● Launched an unbranded promotional campaign which increased awareness of the CD47 MoA and Pfizer clinical program across all five indications by 30% in half a year, including a significant 60% increase in DLBCL awareness.

● Lead cross-functional commercial sub-team, partnering with Market Access, Value and Evidence, and Medical Affairs to develop integrated strategic imperatives and create impactful market development plans for a successful launch in three therapeutic areas and five indications, aligned with corporate objectives, market growth, and revenue targets.

● Secure and manage multi-million-dollar global marketing budget during the annual operating plan process. Collaborate with creative agencies, creating and implementing innovative marketing campaigns in partnership with key regions and countries in preparation for launch. Adept at navigating Medical, Legal and Regulatory promotional review committee.

● Utilize omnichannel approach to implement a comprehensive external scientific communication strategy. Championed the organizational adoption of novel pre - launch strategies which drove digital, social, and traditional media engagement, significantly and consistently exceeding industry benchmarks.

● Oversee Global Congress and KOL engagement strategy to foster HCP education, awareness, and advocacy. Led the development and implementation of 2023 ASH KOL reception which resulted in a 50% increase in awareness and enhanced thought leader confidence in the asset’s differentiation, data, and development program.

● Leverage customer, market, and competitive insights to optimize development program and product profile, resulting in increased market share and revenue forecasts. Ensure strategy is aligned with the evolving treatment landscape.

● Identified and secured five highly desirable external industry collaborations with multiple organizations to optimize combination partner strategy and maximize value of the maplirpacept development program.

● Established relationships and partnered with Patient Advocacy Organizations to educate patients on relevant and accessible clinical trials, resulting in a 25% increase in patient awareness of, and enrollment in, maplirpacept studies. Director, Inflammation & Immunology Commercial Development, 2015 - 2021 Promoted to a leadership role to provide commercial guidance in delivering the Inflammation & Immunology (I&I) strategy to early candidate Research & Development (R&D) teams while representing commercial opportunity to secure senior leadership endorsement. Provided commercial leadership across all stages of the product lifecycle, from pre-clinical to pre- launch.

● Represented the Inflammation & Immunology (I&I) strategy to R&D teams, shaping assets into viable products and optimizing the portfolio to meet Pfizer's strategic goals and revenue targets.

● Shaped the early commercial asset strategy by identifying lead and lifecycle indication sequencing strategy, championing profile attributes that drive revenue forecasts, optimizing pricing and market access and ensuring commercial operational expenses are allocated to ensure product launch success.

● Led cross-functional teams through clinical development decision points, focusing on pipeline assets in Atopic Dermatitis, Psoriasis, Vitiligo, Rheumatoid Arthritis, Lupus, Ulcerative Colitis, Crohn’s Disease, and other auto-immune indications.

● Partnered with regional and local marketing colleagues to align on the commercial opportunity of pipeline assets, including Emerging Markets and International Developed Markets.

● Devised comprehensive pre-launch market development strategy and tactics for local implementation for ritlecitinib

(Vitiligo) and tofacitinib (Ulcerative Colitis), including positioning, messaging, segmentation and product branding.

● Provided strategic commercial insights for Pfizer's business development initiatives, identifying opportunities that deliver significant value and complement the internal I&I portfolio. Successfully led execution of 5 BD deals.

● Delivered leadership - endorsed franchise strategies for the Gastroenterology and Topical Dermatology portfolios to guide development efforts of R&D teams, ensuring alignment with commercially viable product profiles and indications. Senior Brand Manager, Emerging Markets/Global Marketing, Vaccines, 2013 - 2015 Headed promotional campaign development and implementation for Prevenar 13 in collaboration with regional marketing leads. Developed brand strategies into impactful global tactics that drove business results and addressed customer needs. Launched expanded age indication and co-created new campaign and messaging with US and Emerging Markets.

● Served as the Review Committee Captain encompassing medical, legal, and commercial leadership with accountability for overseeing campaign development in a cross-functional, global, matrix organization.

● Developed strategic and operating plans and budgets and managed the marketing materials approval process while ensuring compliance with promotional regulations.

● Selected to serve as an Innovation and Experimentation Champion and Trainer by Vaccines Business Unit leadership by showcasing a commitment to driving progress and creativity in marketing practices.

● Equipped local markets with impactful creative campaigns, while utilizing blended marketing techniques, compelling promotional messaging, and visual representations to drive competitive differentiation Director, XELJANZ Regional Brand Lead, Latin America-Secondment, 2018 - 2019 Brand Manager, Chantix Global Marketing-Secondment, 2012 - 2013 Manager, Business Analytics & Insights, Inflammation, 2010 - 2012 ADDITIONAL RELEVANT EXPERIENCE

IQVIA / IMS Health Blue Bell, PA

Marketing, Senior Consultant

Advised Pfizer's Established Products Business Unit, leading Loss of Exclusivity (LoE) strategies, therapeutic portfolio assessments, competitive intelligence, and lifecycle product enhancements. Achieved $2M+ in revenue, consistently maintained a 100% client satisfaction score, and earned the IMS Excellence Award for outstanding performance in project execution and business development.

EDUCATION AND CERTIFICATIONS

Bachelor of Science (B.S.), Double Major Biology & Spanish Dean’s List with Distinction

Duke University Durham, NC

Contact this candidate